Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy(STIMULUS-AML1) | terminated | Phase 2 | 90 | Novartis Pharmaceuticals |
| 10 |
| Jan 13, 2026 |
| clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 146 | Novartis PharmaceuticalsINDUSTRY | 14 | Jan 13, 2026 | clinicaltrials |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | active not recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jan 13, 2026 | clinicaltrials |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT04203316 | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | active not recruiting | Phase 2 | 1 | Children's Oncology GroupNETWORK | 2 | Jan 9, 2026 | clinicaltrials |
| NCT04966676 | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer(ATLAS) | terminated | Phase 2 | 5 | University Health Network, TorontoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC(TRUST-II) | active not recruiting | Phase 2 | 217 | Nuvation Bio Inc.INDUSTRY | 9 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT01196936 | Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors(LDTam) | active not recruiting | Phase 2 | 84 | University of Alabama at BirminghamOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT05380713 | ......SMARTEST Trial...... | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT07300566 | Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial(FORWARD) | not yet recruiting | Phase 2 | 58 | Joelle HelouOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301866 | A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.(ECT-001-CB-013) | recruiting | Phase 1 / Phase 2 | 7 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04655365 | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.(PROSTEP-002) | active not recruiting | Phase 2 | 50 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT07299409 | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | not yet recruiting | Phase 2 | 24 | Nathalie LevasseurOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies(Galahad) | completed | Phase 2 | 289 | Janssen Research & Development, LLCINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT02001272 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer(EWOC-1) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 6 | Dec 19, 2025 | clinicaltrials |
| NCT03753334 | Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.(RCT-EPAII-BCR) | active not recruiting | Phase 2 | 39 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT04966663 | Using ctDNA to Determine Therapies for Lung Cancer(ctDNA Lung RCT) | recruiting | Phase 2 | 66 | University Health Network, TorontoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05327647 | A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer(BicaBCa) | recruiting | Phase 2 | 160 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05860296 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | terminated | Phase 1 / Phase 2 | 36 | SignalChem Lifesciences CorporationINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT07291557 | PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer | not yet recruiting | Phase 2 | 250 | AHS Cancer Control AlbertaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT02297217 | Chemoradiotherapy for Advanced Esophageal Cancer(PaRCUS) | recruiting | Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT01743131 | Abatacept as GVHD Prophylaxis Phase 2 | completed | Phase 2 | 186 | Boston Children's HospitalOTHER | 2 | Dec 11, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT04204850 | Cabozantinib to Treat Recurrent Liver Cancer Post Transplant | recruiting | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)(KEYNOTE-B61) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Dec 3, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials